Closed-loop insulin delivery for treatment of type 1 diabetes

Замкнутая система доставки инсулина для лечения сахарного диабета 1 типа
Roman Hovorka, David B. Dunger, Daniela Elleri
2011-11-09

artificial pancreasclosed-loop insulin deliverycontinuous glucose monitoringinsulin pumptype 1 diabetes
Type 1 diabetes is one of the most common endocrine problems in childhood and adolescence, and remains a serious chronic disorder with increased morbidity and mortality, and reduced quality of life. Technological innovations positively affect the management of type 1 diabetes. Closed-loop insulin delivery (artificial pancreas) is a recent medical innovation, aiming to reduce the risk of hypoglycemia while achieving tight control of glucose. Characterized by real-time glucose-responsive insulin administration, closed-loop systems combine glucose-sensing and insulin-delivery components. In the most viable and researched configuration, a disposable sensor measures interstitial glucose levels, which are fed into a control algorithm controlling delivery of a rapid-acting insulin analog into the subcutaneous tissue by an insulin pump. Research progress builds on an increasing use of insulin pumps and availability of glucose monitors. We review the current status of insulin delivery, focusing on clinical evaluations of closed-loop systems. Future goals are outlined, and benefits and limitations of closed-loop therapy contrasted. The clinical utility of these systems is constrained by inaccuracies in glucose sensing, inter- and intra-patient variability, and delays due to absorption of insulin from the subcutaneous tissue, all of which are being gradually addressed.
1
Clinical progress has been enabled by wider insulin-pump use and increasing availability of continuous glucose-monitoring technologies.
2
Clinical utility remains limited by sensor inaccuracies, inter- and intra-patient variability, and delays in subcutaneous insulin absorption.
3
Closed-loop insulin delivery combines continuous interstitial glucose sensing with an algorithm-controlled insulin pump to provide real-time glucose-responsive therapy.
4
The artificial pancreas aims to reduce hypoglycemia risk while achieving tighter glucose control in people with type 1 diabetes.
5
These technical limitations are being progressively addressed, supporting further development of closed-loop therapy for type 1 diabetes.

closed-loop insulin delivery systems (artificial pancreas) for type 1 diabetes

clinical effectiveness and limitations of real-time glucose-responsive insulin administration, particularly glycemic control and hypoglycemia risk

Publication Details
Publication Date
2011-11-09
Journal
Publisher
ISSN
Cited by
103
Access Type
Author Information
Authors
Roman Hovorka
David B. Dunger
Daniela Elleri
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%